Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| VINABAS FORMULATIONS SL | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study evaluates the efficacy of Satisens®, a dietary supplement composed of plant extracts, in reducing emotional eating and sweet cravings in healthy adults. The study will analyze hormonal, neurotransmitter, and inflammatory markers to understand the underlying mechanisms.
This study aims to evaluate the efficacy of Satisens®, a dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), and saffron (Crocus sativus), in reducing emotional eating and sweet cravings in healthy adults. The supplement is hypothesized to modulate appetite through neuroendocrine and anti-inflammatory mechanisms.
The study is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to intervention or placebo groups. The intervention group will receive two capsules of Satisens® daily for 8 weeks, with a subgroup continuing for an additional 4 weeks or switching to placebo. The placebo group will receive identical capsules without active ingredients.
Primary outcomes include changes in emotional eating, appetite, sweet cravings, body weight, BMI, waist circumference, and waist-to-hip ratio. Secondary outcomes include blood levels of appetite-related hormones, neurotransmitters, and inflammatory markers.
Emotional eating will be assessed using validated questionnaires (EEQ, VAS, PFS). Blood samples will be analyzed using chromatography and mass spectrometry techniques. Statistical analysis will include paired t-tests or Wilcoxon tests, Mann-Whitney U tests, correlation analysis, and structural equation modeling.
The study has received ethical approval from the Ethics Committee of the Universidad Católica de Valencia San Vicente Mártir (code: UCV/2024-2025/015) and complies with the Declaration of Helsinki and GDPR regulations.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: Satisens® 8 Weeks | Experimental | Participants receive 2 capsules of Satisens® daily for 8 weeks. The supplement contains lemon verbena, hibiscus, saffron, and other plant extracts. Capsules are taken with breakfast or lunch. |
|
| Arm 1.1: Satisens® 12 Weeks | Experimental | Subgroup of Arm 1 continues with Satisens® for an additional 4 weeks (total 12 weeks). Same dosage and administration as initial 8 weeks. |
|
| Arm 1.2: Satisens® 8 Weeks + Placebo 4 Weeks | Experimental | Subgroup of Arm 1 receives Satisens® for 8 weeks followed by placebo for 4 weeks. Placebo capsules are identical in appearance and administration. |
|
| Arm 2: Placebo 8 Weeks | Placebo Comparator | Participants receive placebo capsules for 8 weeks. Capsules are identical in appearance to Satisens® and contain inert ingredients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intervention 1: Satisens® | Dietary Supplement | A dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Emotional Eating Score (EEQ) | Measured using the Emotional Eating Questionnaire (EEQ) to assess changes in emotional eating behavior. Scale Range: 0 to 30 Interpretation: Higher scores indicate worse emotional eating behavior (i.e., greater tendency to eat in response to emotions). | Baseline, Week 8, Week 12 |
| Change in Appetite Score (VAS) | Visual Analog Scale adapted for appetite, including hunger, satiety, fullness, and prospective food consumption. Scale Range: 0 to 100 for each item Interpretation: Higher scores indicate greater satiety and lower appetite. Therefore, a higher PA score reflects a better outcome in terms of appetite control. | Baseline, Week 8, Week 12 |
| Change in Sweet Craving (PFS) | Power of Food Scale adapted to sweet foods to assess psychological craving. Scale Range: 1 to 5 per item (typically 15 items total; total score range: 15 to 75) Interpretation: Higher scores indicate greater psychological craving for sweet foods, thus a worse outcome in the context of this study. | Baseline, Week 8, Week 12 |
| Change in Body Weight | Measured in kilograms (kg) using a calibrated scale with participants in a fasting state. Unit of Measure: Kilograms (kg) Interpretation: A decrease in weight indicates a better outcome. | Baseline, Week 8, Week 12 |
| Change in Body Mass Index (BMI) | Calculated as weight (kg) divided by height squared (m²). Unit of Measure: kg/m² Interpretation: A decrease in BMI indicates a better outcome. | Baseline, Week 8, Week 12 |
| Change in Waist Circumference |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Appetite-Related Hormones | Blood levels of different Appetite-Related Hormones | Baseline, Week 8, Week 12 |
| Change in Neurotransmitter Levels | Blood levels of different Neurotransmitter |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José Enrique Dr. de la Rubia Ortí, PhD in Pharmacy | Universidad Católica de Valencia San Vicente Mártir | Principal Investigator |
| Gonzalo Mariscal Ruiz-Rico | Universidad Católica de Valencia San Vicente Mártir | Principal Investigator |
| Ana Belén Carriquí Suárez | Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad Católica de Valencia San Vicente Mártir - Facultad de Medicina y Ciencias de la Salud | Valencia | Valencia | 46001 | Spain |
Not provided
| Label | URL |
|---|---|
| Official website of Universidad Católica de Valencia San Vicente Mártir, where the study is being conducted. | View source |
| Official profile of Dr. José Enrique de la Rubia Ortí and his research group "El estrés y la enfermedad" at the Catholic University of Valencia. Includes academic background, research lines, and scientific publications. | View source |
Not provided
Individual participant data (IPD) will not be shared due to institutional data protection policies and the nature of the study, which involves sensitive health-related and psychological information. Data will be handled in compliance with the EU General Data Protection Regulation (GDPR) and Spanish data protection laws, and will remain confidential and accessible only to the research team.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098382 | Emotional Eating |
| D050177 | Overweight |
| D009765 | Obesity |
| D001835 | Body Weight |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D005247 | Feeding Behavior |
| D001519 | Behavior |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D013395 | Sucrose |
| ID | Term |
|---|---|
| D004187 | Disaccharides |
| D009844 | Oligosaccharides |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided
This is a prospective, longitudinal, mixed-method, analytical, and experimental clinical trial. Participants will be randomly assigned to one of three groups: an intervention group receiving Satisens® for 8 weeks, a placebo group, and a subgroup of the intervention group that will either continue with Satisens® or switch to placebo for an additional 4 weeks. The study uses a parallel assignment model to compare the effects of the intervention on emotional eating, appetite, and related biomarkers.
Not provided
Not provided
This is a double-blind study. Neither the participants nor the investigators will know whether the subject is receiving Satisens® or placebo. The placebo capsules are identical in appearance and administration schedule to the active product.
|
|
| Intervention 2: Placebo | Dietary Supplement | Identical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch. |
|
|
Measured in centimeters (cm) at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest.
Unit of Measure: Centimeters (cm) Interpretation: A decrease in waist circumference indicates a better outcome.
| Baseline, Week 8, Week 12 |
| Change in Waist-to-Hip Ratio (WHR) | Calculated as waist circumference divided by hip circumference. Unit of Measure: Ratio (unitless) Interpretation: A decrease in WHR indicates a better outcome. | Baseline, Week 8, Week 12 |
| Baseline, Week 8, Week 12 |
| Change in Leptin Levels | Measured in serum using ELISA. Leptin is a hormone secreted by adipocytes that signals satiety to the hypothalamus. Unit of Measure: ng/mL Interpretation: A decrease in leptin levels (in the context of leptin resistance) may indicate improved sensitivity and better appetite regulation. | Baseline, Week 8, Week 12 |
| Change in Adiponectin Levels | Measured in serum using ELISA. Adiponectin is an anti-inflammatory adipokine associated with improved metabolic health and satiety. Unit of Measure: µg/mL Interpretation: An increase in adiponectin levels indicates a better outcome (improved metabolic and inflammatory profile). | Baseline, Week 8, Week 12 |
| Change in Ghrelin Levels | Measured in serum using ELISA. Ghrelin is known as the "hunger hormone" and stimulates appetite. Unit of Measure: pg/mL Interpretation: A decrease in ghrelin levels indicates a better outcome (reduced hunger signaling). | Baseline, Week 8, Week 12 |
| Change in Interleukin-6 (IL-6) Levels | Measured in serum using ELISA (Enzyme-Linked Immunosorbent Assay). Unit of Measure: pg/mL Interpretation: A decrease in IL-6 levels indicates a better outcome (reduced inflammation). | Baseline, Week 8, Week 12 |
| Change in Tumor Necrosis Factor-alpha (TNF-α) Levels | Measured in serum using ELISA (Enzyme-Linked Immunosorbent Assay). Unit of Measure: pg/mL Interpretation: A decrease in TNF-α levels indicates a better outcome (reduced inflammation). | Baseline, Week 8, Week 12 |
| Official website of IVB Wellness Lab, the company collaborating on the clinical trial. Founded by Dr. Isabel Viña Bas, the company develops scientifically backed nutritional supplements, including SatiSens. | View source |
| Official news release from the Catholic University of Valencia announcing the clinical trial on a saffron-based supplement aimed at reducing sweet cravings and emotional eating. | View source |
| Media article discussing the potential of the saffron-based supplement SatiSens as a natural alternative to appetite suppressants, highlighting its role in the clinical trial. | View source |
| D009750 |
| Nutritional and Metabolic Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D000073893 |
| Sugars |